IL193639A - Purified collagen for use as a cellulite treatment drug - Google Patents

Purified collagen for use as a cellulite treatment drug

Info

Publication number
IL193639A
IL193639A IL193639A IL19363908A IL193639A IL 193639 A IL193639 A IL 193639A IL 193639 A IL193639 A IL 193639A IL 19363908 A IL19363908 A IL 19363908A IL 193639 A IL193639 A IL 193639A
Authority
IL
Israel
Prior art keywords
medicament
purified
couagenase
treating cellulite
purified collagenase
Prior art date
Application number
IL193639A
Other languages
English (en)
Hebrew (he)
Other versions
IL193639A0 (en
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of IL193639A0 publication Critical patent/IL193639A0/en
Publication of IL193639A publication Critical patent/IL193639A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
IL193639A 2006-02-22 2008-08-21 Purified collagen for use as a cellulite treatment drug IL193639A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77569006P 2006-02-22 2006-02-22
US11/703,269 US20070224184A1 (en) 2006-02-22 2007-02-07 Method for treating cellulite
PCT/US2007/004752 WO2007100675A2 (en) 2006-02-22 2007-02-22 Collagenase for treating cellulite

Publications (2)

Publication Number Publication Date
IL193639A0 IL193639A0 (en) 2011-08-01
IL193639A true IL193639A (en) 2015-01-29

Family

ID=38325147

Family Applications (1)

Application Number Title Priority Date Filing Date
IL193639A IL193639A (en) 2006-02-22 2008-08-21 Purified collagen for use as a cellulite treatment drug

Country Status (19)

Country Link
US (4) US20070224184A1 (enExample)
EP (1) EP1991258B1 (enExample)
JP (5) JP5775658B2 (enExample)
KR (2) KR20120006063A (enExample)
AU (1) AU2007221225B2 (enExample)
BR (1) BRPI0708186A2 (enExample)
CA (1) CA2643171C (enExample)
DK (1) DK1991258T3 (enExample)
ES (1) ES2553184T3 (enExample)
HR (1) HRP20151182T1 (enExample)
HU (1) HUE025918T2 (enExample)
IL (1) IL193639A (enExample)
MX (1) MX2008010767A (enExample)
NZ (1) NZ570642A (enExample)
PL (1) PL1991258T3 (enExample)
PT (1) PT1991258E (enExample)
RS (1) RS54372B1 (enExample)
SI (1) SI1991258T1 (enExample)
WO (1) WO2007100675A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
CA2593038C (en) * 2005-01-21 2015-03-17 Advance Biofactures Corporation Methods for treating adhesive capsulitis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
WO2008008468A2 (en) * 2006-07-14 2008-01-17 Duncan Diane I Compositions and methods for fat reduction
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
JP5284239B2 (ja) * 2009-10-07 2013-09-11 株式会社メタコ スクリーン装置
FR2966734B1 (fr) 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
AU2012325941A1 (en) * 2011-10-21 2014-05-15 Auxilium International Holdings, Inc. Method of treating or reducing EFP
EP4276180B1 (en) 2012-01-12 2026-04-22 Endo Biologics Limited Clostridium histolyticum enzyme
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
US9744138B2 (en) 2013-03-15 2017-08-29 Biospecifics Technologies Corp. Treatment method and product for uterine fibroids using purified collagenase
US10117892B2 (en) 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
IL327169A (en) 2017-03-01 2026-05-01 Endo Ventures Ltd A method for assessing and treating cellulite
US11473074B2 (en) 2017-03-28 2022-10-18 Endo Global Aesthetics Limited Method of producing collagenase
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020058755A1 (en) * 2018-09-18 2020-03-26 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
CN113382714A (zh) 2019-01-06 2021-09-10 恩多全球美学有限公司 胶原酶制剂及其制备方法
CA3157517A1 (en) 2019-10-15 2021-04-22 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
WO2021108751A1 (en) * 2019-11-26 2021-06-03 Standard Of Care Corporation Hyaluronidase compositions and methods of using same to treat cellulite
CA3252851A1 (en) * 2022-05-10 2023-11-16 Endo Global Aesthetics Limited Collagenase-mediated methods for reducing bruising in a subject with cellulite

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
JP3028852B2 (ja) * 1994-06-24 2000-04-04 ロシュ ダイアグノスティックス コーポレーション ヒストリチクス菌から得られるコラゲナーゼおよび２つの他のプロテアーゼの精製混合物
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) * 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
CA2317066A1 (en) * 1997-10-03 1999-04-15 Lavipharm Laboratories, Inc. A prolamine-plant polar lipid composition, its method of preparation and applications thereof
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
AU6918700A (en) * 1999-08-20 2001-03-19 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
CA2593038C (en) * 2005-01-21 2015-03-17 Advance Biofactures Corporation Methods for treating adhesive capsulitis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
US20210169844A1 (en) * 2019-12-10 2021-06-10 Tulex Pharmaceuticals Inc. Compositions and methods for treating epilepsy, seizures and other conditions

Also Published As

Publication number Publication date
JP6853331B2 (ja) 2021-03-31
JP6498167B2 (ja) 2019-04-10
HRP20151182T1 (hr) 2016-01-01
WO2007100675A3 (en) 2007-11-15
AU2007221225A1 (en) 2007-09-07
KR20120006063A (ko) 2012-01-17
DK1991258T3 (en) 2015-11-16
ES2553184T3 (es) 2015-12-04
CA2643171C (en) 2018-10-02
MX2008010767A (es) 2008-09-01
IL193639A0 (en) 2011-08-01
US20070224184A1 (en) 2007-09-27
BRPI0708186A2 (pt) 2011-05-24
SI1991258T1 (sl) 2016-02-29
NZ570642A (en) 2012-03-30
US10123959B2 (en) 2018-11-13
US20160279046A1 (en) 2016-09-29
PL1991258T3 (pl) 2016-04-29
JP2016204396A (ja) 2016-12-08
JP2020015771A (ja) 2020-01-30
CA2643171A1 (en) 2007-09-07
EP1991258A2 (en) 2008-11-19
JP2009527570A (ja) 2009-07-30
JP2018199733A (ja) 2018-12-20
EP1991258B1 (en) 2015-08-12
PT1991258E (pt) 2015-11-24
RS54372B1 (sr) 2016-04-28
JP2015134840A (ja) 2015-07-27
WO2007100675A2 (en) 2007-09-07
US20220249348A1 (en) 2022-08-11
JP6649449B2 (ja) 2020-02-19
HUE025918T2 (en) 2016-05-30
US20190053995A1 (en) 2019-02-21
JP5775658B2 (ja) 2015-09-09
AU2007221225B2 (en) 2010-02-11
KR20080108996A (ko) 2008-12-16

Similar Documents

Publication Publication Date Title
WO2005082339A3 (en) Medicaments and methods for treating headache
WO2007081975A3 (en) Method of treating multiple sclerosis
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
WO2007100675A3 (en) Collagenase for treating cellulite
JP2018199733A5 (enExample)
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
WO2009129531A3 (en) Bupivacaine formulation in a polyorthoester carrier
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
MX2009002893A (es) Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
WO2009129527A3 (en) Baclofen formulation in a polyorthoester carrier
WO2007143607A3 (en) Method of treating atrophic vaginitis
NO20023473L (no) Sammensetninger for levering av en kortisol antagonist
MX392388B (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe)
ATE476981T1 (de) Zusammensetzungen zur bekämpfung von beta- lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
PH12015501373A1 (en) Injectable depot formulation comprising optically active tolvaptan and process of producing the same
WO2008114376A1 (ja) メラニン生成抑制組成物
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2007100590A3 (en) Methods for treating cellulite
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
WO2007087154A3 (en) Methods for enhancing therapeutic effects of a neurotoxin
WO2006078870A3 (en) Methods for treating adhesive capsulitis
Toivonen et al. Etoricoxib pre‐medication combined with intra‐operative subacromial block for pain after arthroscopic acromioplasty
SG160323A1 (en) Methods for controlling angiogenesis and cell proliferation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed